1. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM and Karstaedt AS. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med. 2015;16(8):468-76.
2. Longley N, Jarvis JN, Meintjes G, Boulle A, Cross A, Kelly N, et al. Cryptococcal Antigen Screening in persons Initiating ART in South Africa: A Prospective Cohort Study. Clin Infect Dis. 2016;62(5):581-587.
3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873-881.
4. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16(7): 1031-8.
5. Larson BA, Rockers PC, Bonawitz R, Sriruttan C, Glencross DK, Cassim N, et al. Screening HIV-Infected persons with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. PLoS One. 2016;11(7):e0158986.
6. Awotiwon AA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV‐positive people. Cochrane Database Syst Rev. 2018;2018(8): CD004773.
7. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.
8. Sathyanarayanan V, Razak A, Chakraborty J. Clinical profile of disseminated cryptococcal infection – a case series. Asian Pacific Trop Med. 2010;3:818–20
9. Kaplan JE, Vallabhaneni S, Smith RM, Chideya-chihota S, Chehab J and Park B. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. JAIDS. 2015;68(Suppl 3):331-339.
10. Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR. Comparison of Cryptococcal Antigenemia between Antiretroviral Naïve and Antiretroviral Experienced HIV Positive persons at Two Hospitals in Ethiopia. PLoS One. 2013;8(10):e75585.
11. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R and Harrison TS. Screening for cryptococcal antigenemia in persons accessing an antiretroviral treatment program in South Africa. Clin Infect Dis. 2009);48(7):856-62.
12. Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing Cryptococcosis Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. Curr Trop Med Rep. 2015;2(2): 81-9.
14. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers’ Manual: 2016 edition. Australia: The Joanna Briggs Institute; 2016.
15. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
16. Temfack E, Bigna JJ, Luma HN, Spijker R, Meintjes G, Jarvis JN, et al. Impact of routine cryptococcal antigen screening and targeted pre-emptive fluconazole therapy in antiretroviral naive HIV-infected adults with less than 100 CD4 cells/μL: a systematic review and meta-analysis. Clin Infect Dis. 2018;doi: 10.1093/cid/ciy567
17. Huang Y, Huang X, Luo Y, Zhou Y, Tao X, Chen H, et al. Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected persons: A Meta-Analysis of Key Evidence to Support WHO Recommendations. Front Pharmacol. 2018;9:890.
18. Ssekitoleko R, Kamya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. Future Virol. 2013;8(9).
19. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;66(suppl_2):S152-S159.
20. Chariyalertsak S, Supparatpinyo K, Sirisanthana T and Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in persons with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. 2002;34(2):277-84.
21. Manfredi R, Mastroianni A, Coronado OV and Chiodo F. Fluconazole as prophylaxis against fungal infection in persons with advanced HIV infection. Arch Intern Med. 1997;157(1):64-9. PMID: 8996042
22. Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis. 2011;11:933–41.
23. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in persons with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1999;28(5):1049-56.
24. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51: 448-55.
25. Kapoor SW, Magambo KA, Kalluvya SE, Fitzgerald DW, Peck RN, Downs JA. Six-month outcomes of HIV-infected persons given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. AIDS. 2015; 29(18):2473-8.
26. Borges MASB, de Araújo Filho JA, Oliveira BJS, Moreira IS, de Paula VV, de Bastos AL, et al. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil. PLoS One. 2019;14(7):e0219928.
27. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization.2015. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en Assessed September 2015.